NCT06984627 - A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

August 25, 2026

Study Completion Date

September 23, 2026

Conditions

Graves' Disease

Interventions

DRUG

Rilzabrutinib dose 1

Pharmaceutical form:Tablet-Route of administration:Oral

DRUG

Rilzabrutinib dose 2

Pharmaceutical form:Tablet-Route of administration:Oral

Trial Locations (12)

28211

RECRUITING

Investigational Site Number : 3800001, Charlotte

31008

RECRUITING

Investigational Site Number : 7240001, Pamplona

45147

RECRUITING

Investigational Site Number : 2760002, Essen

56126

RECRUITING

Investigational Site Number : 3800002, Pisa

60590

RECRUITING

Investigational Site Number : 2760001, Frankfurt am Main

90127

RECRUITING

Investigational Site Number : 3800003, Palermo

T2N 4L7

RECRUITING

Investigational Site Number : 1240003, Calgary

V3T 2V6

RECRUITING

Investigational Site Number : 1240002, Surrey

J1H 5N4

RECRUITING

Investigational Site Number : 1240001, Sherbrooke

08036

RECRUITING

Investigational Site Number : 7240002, Barcelona

MK6 5LD

RECRUITING

Investigational Site Number : 8260003, Milton Keynes

NE1 4LP

RECRUITING

Investigational Site Number : 8260001, Newcastle upon Tyne